DIABESITY

"Obesity, Type 2 diabetes and the increased risk of cancer and cancer-related Mortality; the study of Molecular Mechanisms and potential therapeutic modalities."

Coordinatore	TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY    more  Organization address address: TECHNION CITY - SENATE BUILDING city: HAIFA postcode: 32000 contact info Titolo: Mr. Nome: Mark Cognome: Davison Email: send email Telefono: +972 4 829 3097 Fax: +972 4 823 2958
Nazionalità Coordinatore	Israel [IL]
Totale costo	250˙106 €
EC contributo	250˙106 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2011-IIF
Funding Scheme	MC-IIF
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-10-01   -   2014-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY  Organization address address: TECHNION CITY - SENATE BUILDING city: HAIFA postcode: 32000 contact info Titolo: Mr. Nome: Mark Cognome: Davison Email: send email Telefono: +972 4 829 3097 Fax: +972 4 823 2958	IL (HAIFA)	coordinator	250˙106.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Epidemiological studies have clearly demonstrated that obesity and Type 2 diabetes are associated with an increased risk of developing common cancers including breast and colon cancer. They are also associated with increased cancer related mortality. While the mechanisms involved in this association are not yet defined, insulin resistance, hyperinsulinemia, hyperlipidemia, hyperglycemia and inflammatory cytokines are thought to be involved. Our studies, using separate mouse models of obesity or Type 2 diabetes, have replicated the increased association of these conditions and breast cancer. We have shown that endogenous hyperinsulinemia maybe an important contributing factor in the increased cancer risk. We propose to extend these studies in a number of directions. Firstly to confirm the findings using a mouse colon cancer cell lines. We will also study metastases, using a specific breast cancer cell line that spreads to the lungs and colon cancer that spreads to the liver. In these mouse experiments we will use specific blockers to the insulin and IGF-1 receptors to determine if the role of endogenous hyperinsulinemia is indeed a major factor in metastases and through which receptor it propagates a signaling cascade. Studies on the molecular mechanisms will be carried out on cells in culture and in the tissue samples from the tumors and metastases from lung and liver. We have also developed a model of hyperlipidemia and cancer and preliminary studies in our model suggest that, hyperlipidemia maybe another contributing factor in the connection between obesity/Type 2 diabetes and cancer and cancer metastases. This model, using breast and colon cancer, will be studied to identify the causative connection between this metabolic disorder and cancer. Overall the plan is to identify specific causality that will help design new therapeutic agents to deal with the growing problem of cancer in obese and diabetic patients.'